Biopharmaceutical giant Gilead Sciences has commenced construction of a 180,000-square-foot Pharmaceutical Development and Manufacturing Technical Development Center at its California headquarters. The facility aims to accelerate next-generation biologics innovation and manufacturing efficiency through flexible pilot labs, digital integration, and robotics. This investment forms part of Gilead’s broader $32 billion U.S. commitment to bolster pipeline development across virology, oncology, and inflammation areas, forecasted to enhance domestic biologics capacity and support innovation-driven growth.